It is currently Tue Sep 01, 2015 5:30 am

News News of Campath (Lemtrada, Alemtuzumab)

Site map of Campath (Lemtrada, Alemtuzumab) » Forum : Campath (Lemtrada, Alemtuzumab)

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

MS drug Lemtrada does not benefit patients, FDA panel says

Lemtrada hasn’t proven to help against disability in the treatment of relapsing multiple sclerosis, said U.S. advisers who questioned whether the company’s studies were conducted well enough to assess the drug.

While the U.S. Food and Drug Administration advisory panel decided that potential safety risks don’t preclude approval of Lemtrada, its members voted 14-2 that the drug didn’t help improve a patient’s disability. The agency isn’t required to accept the recommendations of its advisers..... Read ...
Read more : MS drug Lemtrada does not benefit patients, FDA panel says | Views : 1116 | Replies : 0


FDA staff says new oral MS drug Lemtrada may be too risky

Sanofi’s multiple sclerosis treatment Lemtrada may not offer enough benefit to patients to outweigh risks including cancer, U.S. regulators said. The French drugmaker’s shares fell.

Lemtrada’s “serious and potentially fatal safety issues,” which include the risk of autoimmune and thyroid diseases, may make the medicine too dangerous to approve unless there is substantial clinical benefit shown, Food and Drug Administration staff said in a report today. Agency reviewers also questioned whether Sanofi conducted adequate trials ...
Read more : FDA staff says new oral MS drug Lemtrada may be too risky | Views : 1239 | Replies : 1


Alemtuzumab 3-year data show durable effect on MS disability

Latest data from the CARE-MS II extension study show that alemtuzumab (Lemtrada, Genzyme/Sanofi) has a durable effect on disability in multiple sclerosis (MS), with the mean Expanded Disability Status Scale (EDSS) score at 3 years still below that at baseline.<br><br>

These new data were presented in a poster at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) last week...... Read More - http://www.ms-uk.org/lemtrada
Read more : Alemtuzumab 3-year data show durable effect on MS disability | Views : 1258 | Replies : 0


Oral MS drug Lemtrada approved by European Commission

Genzyme, a Sanofi company announced today that the European Commission has granted marketing authorization for Lemtrada(TM). This follows the August 30th approval of Aubagio(R). The company intends to begin launching both products in the EU soon.

"The approvals of Lemtrada and Aubagio in the European Union represent an important milestone for Genzyme and demonstrate our focus on scientific innovation and commitment to multiple sclerosis patients," said Genzyme CEO and President, David Meeker, M.D. "This is ...
Read more : Oral MS drug Lemtrada approved by European Commission | Views : 1298 | Replies : 1


Got all it's gonna give me

I went to my neuro clinic for my monthly blood draw. The trial coordinator asked me how I was doing since my last dose of alemtuzumab (it's been over a year and I've dosed four times in total). I told her that I was slowly declining and she said that I should begin to look at other treatment options, that alemtuzumab had done all its going to do for me. I can continue and should ...
Read more : Got all it's gonna give me | Views : 1687 | Replies : 1


Genzyme receives positive CHMP opinion for Lemtrada™

Genzyme receives positive CHMP opinion for Lemtrada™ (alemtuzumab) in Europe

CHMP also Recommends NAS Designation for Aubagio® (teriflunomide) Following Positive Opinion on Approval in March 2013

Genzyme announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for approval of Lemtrada™ (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging ...
Read more : Genzyme receives positive CHMP opinion for Lemtrada™ | Views : 1354 | Replies : 0


Mechanism found for Alemtuzumab side effect

Researchers think they may have figured out why a drug that is highly effective against one autoimmune disease can sometimes trigger another.... Read More - http://www.ms-uk.org/index.cfm/lemtrada
Read more : Mechanism found for Alemtuzumab side effect | Views : 1609 | Replies : 1


Infusion duration

I have a simple question for anyone that has been on Lemtrada. How long does each individual
infusion take? Is it about an hour or all day?

I just stopped Tysabri after 73 infusions (JCV+). I am waiting for my Tecfidera script to get here.

I like to stay current with what new treatments are coming.
Nothing looks more promising than Lematrada to me. 5 infusions then a year later 3 more.
If I understand ...
Read more : Infusion duration | Views : 1519 | Replies : 1


Genzyme boasts of durable response to MS drug Lemtrada

Genzyme boasts of durable response to MS drug Lemtrada

Looking ahead to a prospective FDA approval of its experimental multiple sclerosis drug Lemtrada and a new product launch into a competitive and fast-changing market, Genzyme executives today rolled out positive data from a one-year extension study of its pivotal Phase III trial that gives the company some boasting rights for a drug that demonstrated a durable response in most patients..... Read More - http://www.ms-uk.org/index.cfm/lemtrada
Read more : Genzyme boasts of durable response to MS drug Lemtrada | Views : 1697 | Replies : 2


Alemtuzumab lessens relapses, improves disability in MS

Alemtuzumab lessens relapses, improves disability in MS - studies

Image

Two new trials offer proof that a leukemia drug long used to treat multiple sclerosis works better than a common treatment.

When compared with the widely used drug interferon beta, the leukemia drug alemtuzumab reduced relapse rates by half, researchers say.

Alemtuzumab Reverses Disability in Some

Alemtuzumab has been used to treat MS for close to two decades, but it has never been approved for ...
Read more : Alemtuzumab lessens relapses, improves disability in MS | Views : 2465 | Replies : 3


 

Login  •  Register


Statistics

Total posts 227096 • Total topics 23947 • Total members 15271


Contact us | Terms of Service